The VERVE-102 base editor appeared to be safe and reduce low-density lipoprotein cholesterol levels by up to 62 percent in a Phase I open-label, single-ascending dose trial.

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

In what could be one of the biggest breakthroughs in treating heart disease, a small study showed that an experimental ...

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...

Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...

Precision gene editing can be achieved by base editing, nucleotide editing, or editing of small or large gene fragments. The specific mechanisms include various DNA repair pathways. Many precision ...

LDL Reduction: Studies have found that this therapy successfully reduced LDL cholesterol by up to 62 percent. Let's explain ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.

Sickle-cell disease and β-thalassemia are inherited blood disorders that are caused by mutations in the HBB gene (encoding a component of adult hemoglobin) and are characterized by severe, lifelong ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...